BioSpace News Archive

Data from 25,800 participants in Phase 3 trial in India, received vaccine or placebo in a 1:1 ratio showed that the vaccine candidate was well tolerated and demonstrated 81% efficacy in preventing COVID-19 in those without prior infection after the second dose. Clinical trial to continue through to final analysis at 130 confirmed cases in order to gather further data and to evaluate the efficacy of COVAXIN in additional secondary study endpoints.

TCR 2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage immunotherapy company with a pipeline of novel T cell therapies for patients suffering from cancer, today announced that management will present an update on Company progress at two upcoming conferences in March using a virtual platform. Ian Somaiya, Chief Financial Officer of TCR 2 Therapeutics, will present corporate presentation at the H.C. Wainwright Global Life Sciences Conference

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that Viracta will participate at the H.C. Wainwright Global Life Sciences Conference, being held March 9-10 , 2021.

- PRA023 is a TL1A antibody targeting both inflammation and fibrosis in patients with ulcerative colitis and Crohn’s disease - - PRA023 is being developed to be used in combination with a companion diagnostic to identify responders in novel precision medicine approach -

ScienceMedia, the leader in life sciences and clinical trial education, has again demonstrated its commitment to innovation by launching a new version of SMi Trial , the company’s risk-based protocol training solution, and expanding the ScienceMedia team with the addition of a new Product Director, Robert Geckeler

eXIthera Pharmaceuticals, a clinical-stage biotechnology company focused on addressing bleeding complications associated with currently available antithrombotic agents through the targeted inhibition of coagulation Factor XIa, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for EP-7041,

The Defense Advanced Research Projects Agency (DARPA) has awarded the Georgia Tech Research Institute (GTRI) a seed other transaction agreement as part of their SenSARS program to develop a sensing platform to detect airborne SARS-CoV-2 particles.

Xentria Inc., a biopharmaceutical company focused on developing novel biologics and biosimilars to address unmet clinical needs, today announced that it submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) on February 26, 2021.

Janux Therapeutics today announced the close of a $56 million Series A financing led by Avalon Ventures and joined by new investors, OrbiMed and RA Capital Management, as well as existing investors, Bregua and Correlation Ventures

Expanded Partnership Demonstrates Value of Technology-Enabled Services and Autonomous Pharmacy Vision